A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Completed
Hoffmann-La Roche
Phase 2
This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of
multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are
treated with a stable dose of metformin. Patients will be randomized to receive either
subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or
20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen
throughout the study. The anticipated time on study treatment is
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Completed
Hoffmann-La Roche
Phase 2
This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different
doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose
of metformin. Patients will be randomized to receive either subcutaneous placebo, or
subcutaneous GLP-1 analogue (at a dose of 20mg, or a starting dose of 20mg escalating to
either 30mg or 40mg), weekly. All patients will continue on their existing metformin
treatment regimen throughout the study. The anticipated time on study treatment is
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
Completed
Hoffmann-La Roche
Phase 3
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared
with exenatide in patients with type 2 diabetes mellitus inadequately controlled with
metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive
taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly)
or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in
a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either
alone or in combination. The anticipated time on study treatment is 3+ years, and the target
sample size is >500 individuals.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
